Kirloskar Technologies launches Non- Invasive Magnetic Resonance guided Focused Ultrasound System (MRgFUS) in India
 |
|---|
| L-R Rishma PaiShrinivas DesaiW M GedroycMr Amardeep Sethi -CEO Kirloskar TechnologiesCol Masand Roni Yegel-VPInsightec at the Launch of Exablate 2000 |
2010-01-18 10:55:57 -
Jaslok Mumbai the first hospital to install ExAblate 2000 With the launch of ExAblate 2000 in India by Kirloskar Technologies, a leading provider of high technology life saving devices, the treatment of Uterine Fibroids amongst Indian women receives a huge boost. The Non Invasive Magnetic Resonance guided Ultrasound surgery machine (MRgFUS) reduces chances of infertility and offers significant advantages over the existing treatments. The new Technology will help women
reduce the risk of removal of uterus, which is very high in case of surgeries.
With the first ExAblate 2000 installed at Jaslok Mumbai, it would be the first hospital in India to offer this treatment to patients. This major technology development in the healthcare industry is expected to be a boon to the medical fraternity and specially to the women who currently undergo a rigorous procedure in the treatment for uterine fibroids. Study says that 20 to 40% of women age 35 and older have uterine fibroid of a significant size with Indian women being at a far higher risk for fibroids with as many as 50 % having fibroids of various sizes.
Discussing during the launch of this new equipment in India Dr W.M Gedroyc, Medical Director, MRU, St Mary’s Hospital, London said “ It is important to properly identify and successfully treat patients with uterine fibroids and one of the primary objectives of KTPL & Insightec is to create awareness about this disease not only amidst the patients/end beneficiaries but also within the medical practitioners “ One of the prominent highlights of this treatment system is that it does not require any anesthesia or hospitalization for the patient. Hence women suffering from this disease do not have to undergo the painful trauma of surgery.
Some facts on Uterine Fibroids :
1 ) Uterine Fibroids occur in every four to five women
2) Uterine Fibroids also known as uterine leimyomata are the most common non cancerous tumors in women of childbearing age
3) Women who are obese or overweight have a slightly higher risk for developing uterine fibroids than women of normal weight
4) Generally occurs in women between 30’s to 40’s
5) In India it is found that this disease is common between the age group of 21-30 – 30 % and 30 + is 30 %
Commenting on the uniqueness of ExAblate 2000 Mr. Amardeep Sethi, CEO Kirloskar Technologies said, “Uterine fibroids result in more in-patient hospital days than AIDS, breast cancer, dementia, etc. It is estimated that women lose 5-10 million work days annually because of this. In addition to this the recovery stage of a woman post-surgery is the most crucial. In such circumstances the use of ExAblate 2000 turns out to be a much easier and comfortable method compared with current invasive treatment options“.
ExAblate 2000 is a way forward to a new phase of Fibroid surgery in India. This equipment is approved by the U.S Food and Drug Administration (FDA) in Oct 2004.
Additional applications of ExAblate 2000 under investigation are for Brain tumors, Liver tumors, Breast cancer, Prostate cancer, Bone metastases.
About KTPL:
Kirloskar Technologies is one of the leading suppliers of high-tech medical equipments in India. It is part of the 100 year old multi –billion dollar Kirloskar Group. With over 250 installations in 175 major government hospitals, medical colleges and private hospitals, the KTPL is the largest player in the Radio Therapy market.
About Insightec:
InSightec Ltd. developed ExAblate 2000, a product that integrates magnetic resonance imaging with focused ultrasound energy as a treatment modality for patients with serious diseases. The company was founded in 1999 and is headquartered in Tirat Carmel, Israel with an additional office in Dallas, Texas.
